First tranche delivered, larger tranches en route: the same engine that just produced has visibly more already scheduled
The model's full reasoning — Q4 2022 call → NOWe need to determine if management describes an identifiable engine of new business with both a first tranche actually landed and larger tranches already in motion. Let's analyze the transcript. Key candidates: 1. Fazirsiran (AAT program) with Takeda: SEQUOIA data in, Phase 3 design submitted to FDA, waiting feedback. Phase 3 to start Q1 2023. But is there a "first tranche" landed? The Phase 2 data is in, but that's not a business engine. The program is partnered, but the revenue recognition is from collaboration. Not a new engine. 2. ARO-APOC3 and ARO-ANG3: Phase 2 studies ongoing, interim data presented. Plans for Phase 3. But no product launched, no revenue from these yet. They are in development. Not a landed business. 3. Pulmonary programs: ARO-RAGE, ARO-MUC5AC, ARO-MMP7. Phase 1/2 studies. No product. 4. ARO-C3: Phase 1/2, no product. 5. 20 in '25 program: plan to have 20 drugs in clinical trials by 2025. That's a pipeline plan, not a landed engine. 6. Royalty sale to Royalty Pharma: This is a financing transaction. They sold future royalties from olpasiran for $250M upfront plus up to $160M. This is a one-time deal, not an engine with tranches. The $250M is a lump sum, not a first tranche with more to come. The additional $160M is contingent on milestones, not a committed continuation. Also, this is not a business engine like a product launch. 7. Partnerships with five companies: They expect milestone payments from each over next 12 months. But that's not a specific engine with a first tranche landed and larger tranches in motion. It's just expected future payments. 8. The "clarity" about pipeline and programs: Not an engine. The question asks for an identifiable engine of new business—such as a specific contract, program, product, facility, customer relationship, market, or expansion—where a first tranche has actually landed (delivered, shipped, completed, opened, billed, recognized) in the just-reported period, and larger tranches are already in motion behind it. Looking at the transcript, management talks about progress in clinical trials, but no product has been launched or sold. The only concrete business transaction is the Royalty Pharma deal, but that's a sale of future royalties, not a business engine with multiple tranches. The $250M is upfront, and the $160M is contingent on milestones, not a committed continuation.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| ATAT | Atour Lifestyle Holdings Limited | Q1 2024 | 2024-05-23 | B+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| E | Eni S.p.A. | Q1 2024 | 2024-04-24 | B+ |
| FRPH | FRP Holdings, Inc. | Q4 2023 | 2024-03-07 | C+ |
| ZLAB | Zai Lab Limited | Q4 2023 | 2024-02-28 | C |
| VMI | Valmont Industries, Inc. | Q4 2023 | 2024-02-22 | C |
| TBLA | Taboola.com Ltd. | Q3 2023 | 2023-11-08 | B+ |
| JLL | Jones Lang LaSalle Incorporated | Q3 2023 | 2023-11-02 | F |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| CLNE | Clean Energy Fuels Corp. | Q2 2023 | 2023-08-09 | C+ |
| LUCD | Lucid Diagnostics Inc. | Q1 2023 | 2023-05-16 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| ARE | Alexandria Real Estate Equities, Inc. | Q4 2022 | 2023-01-31 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| CDMO | Avid Bioservices, Inc. | Q3 2022 | 2022-03-08 | B+ |
| DG | Dollar General Corporation | Q2 2021 | 2021-08-26 | A |
| DOV | Dover Corporation | Q2 2021 | 2021-07-20 | B+ |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| FEIM | Frequency Electronics, Inc. | Q1 2019 | 2018-09-13 | B+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| MGA | Magna International Inc. | Q1 2018 | 2018-05-10 | B+ |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| HR | Healthcare Realty Trust Incorporated | Q1 2017 | 2017-05-08 | A |
| BDN | Brandywine Realty Trust | Q1 2017 | 2017-04-21 | C+ |
| WTS | Watts Water Technologies, Inc. | Q4 2016 | 2017-02-10 | B |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| MTRX | Matrix Service Company | Q3 2016 | 2016-05-05 | D |
| CLF | Cleveland-Cliffs Inc. | Q1 2016 | 2016-04-29 | F |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
CDMO · Q3 2022 → YESThe question is about whether management describes ONE identifiable engine of new business that meets two criteria: NO The transcript describes the first phase of the Myford expansion as now operational and scheduling client projects, with management noting they are already utilizing the new space and that an extra $5 million is arguably in backlog attributable to it.
LINC · Q1 2024 → YESThe question is about whether management describes ONE identifiable engine of new business that meets two criteria: YES The transcript identifies the new-campus expansion strategy as the engine. East Point opened in Q1 with 29 starts and $90k revenue (first tranche, concrete and delivered).
LTRX · Q3 2024 → YESThe question is about whether management describes one identifiable engine of new business that meets two criteria: a first tranche has actually landed in the just-reported period, and larger tranches...